- Home
- PLRX vs CCIF Comparison
PLRX vs CCIF Comparison
Compare PLRX & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLRX | CCIF |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.3M | 101.1M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PLRX | CCIF |
|---|---|---|
| Price | $1.31 | $4.71 |
| Analyst Decision | Hold | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $3.79 | N/A |
| AVG Volume (30 Days) | ★ 945.1K | 76.9K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 25.90% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $7.43 |
| 52 Week High | $13.46 | $10.16 |
Technical Indicators
Market Signals| Indicator | PLRX | CCIF |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 41.32 |
| Support Level | $1.20 | $4.55 |
| Resistance Level | $1.36 | $4.80 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 64.71 | 48.21 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.